Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk

Dow Jones11-12

1417 ET - JPMorgan analysts think Sarepta Therapeutics' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's implied guidance for its Duchenne muscular dystrophy treatment, called Elevidys. But that selloff is a fresh opportunity: They say the stock's valuation is still underappreciating the potential future sales of the treatment. They say that investors are not pricing in the full potential for Elevidys's label expansion, presenting a buying opportunity. The FDA expanded Elevidys's approval to individuals 4 years old and up in June. Shares fall 2.8%. (ben.glickman@wsj.com; @benglickman)

(END) Dow Jones Newswires

November 11, 2024 14:17 ET (19:17 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482875494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 03:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482875494","market":"other","top_or_hot":-1,"title":"Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1417 ET - JPMorgan analysts think <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's implied guidance for its Duchenne muscular dystrophy treatment, called Elevidys. But that selloff is a fresh opportunity: They say the stock's valuation is still underappreciating the potential future sales of the treatment. They say that investors are not pricing in the full potential for Elevidys's label expansion, presenting a buying opportunity. The FDA expanded Elevidys's approval to individuals 4 years old and up in June. Shares fall 2.8%. (ben.glickman@wsj.com; @benglickman) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2024 14:17 ET (19:17 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 03:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1417 ET - JPMorgan analysts think Sarepta Therapeutics' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2482875494","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482875494","pubTimestamp":1731352620,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1417 ET - JPMorgan analysts think Sarepta Therapeutics' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's implied guidance for its Duchenne muscular dystrophy treatment, called Elevidys. But that selloff is a fresh opportunity: They say the stock's valuation is still underappreciating the potential future sales of the treatment. They say that investors are not pricing in the full potential for Elevidys's label expansion, presenting a buying opportunity. The FDA expanded Elevidys's approval to individuals 4 years old and up in June. Shares fall 2.8%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","SRPT":"Sarepta Therapeutics"},"translate_title":"Sarepta的估值被视为一颗容易下咽的药丸——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"1417 ET - JPMorgan analysts think Sarepta Therapeutics' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's implied guidance for its Duchenne muscular dystrophy treatment, called Elevidys. But that selloff is a fresh opportunity: They say the stock's valuation is still underappreciating the potential future sales of the treatment. They say that investors are not pricing in the full potential for Elevidys's label expansion, presenting a buying opportunity. The FDA expanded Elevidys's approval to individuals 4 years old and up in June. Shares fall 2.8%. (ben.glickman@wsj.com; @benglickman) \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 14:17 ET (19:17 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482875494"}